INTRODUCTION
Adenomatous hyperplasia of gallbladder is the most common benign mesenchymal proliferation, accounting for more than 40% of tumor-like lesions of the organ [1, 2] . 
CASE REPORT
A 54-year-old male patient presented to the outpatient clinic with complaints of a palpable mass in the right upper quadrant of the abdomen, nausea and some weight loss. On physical examination, a firm and fixed mass was found in the abdomen. The levels of hepatic and biliary enzymes were normal. The tumor markers (carcinoembyonic antigen, carbohydrate antigen 19-9, alpha-fetoprotein) were also normal. Endoscopic ultrasound examination revealed a gallbladder mass without direct invasion of liver parenchyma and duodenum (Fig. 1) . Abdominal com-thesurgery.or.kr 14.5) in the entire gallbladder (Fig. 4 ).
We performed a simultaneous radical cholecystectomy (S4b + S5 segmentectomy), omentectomyand small bowel segmental resection. We also did dissection of lymph nodes around the hepatoduodenal ligaments and the celiac (doxorubicin, ifosfamide, mesna), MAID, and so on [6, 7] .
The single agents include dacarbazine, doxorubicin, epirubicin, gemcitabine, ifosfamide, liposomal doxorubicin and temozolomide [8, 9] .
The prognosis of sarcoma and leiomyosarcomas of the gallbladder is dismal, the five year survival rate being less than 5%. This is due to the fact that at the time of the diagnosis or surgery. Almost 75% of cases involve the liver [10] .
Our patient was also diagnosed at an advanced stage, but he had no distant organ metastasis. Because R0 resection is expected in this case, an aggressive surgical approach was attempted. However, soon after, multiple liver metastasis and peritoneal seeding metastasis were detected in postoperative evaluations. Therefore additional aggressive multimodality treatments such as surgery with chemotherapy are the only way to increase the survival rate.
In conclusion, the five year survival rate of leiomyosarcoas of the gallbladder is less than 5%. However for young and healthy patients with leiomyosarcomas of the gallbladder, aggressive surgical treatment followed by adjuvant chemotherapy should increase the survival rate despite high mortality and morbidity. Because of limited ex-perience with this disease, there is no consensus about management. Further studies are needed to confirm the benefit of aggressive treatment for patients with leiomyosarcoma of the gallbladder. Also surgeons will have to tread very carefully in selection of candidates for surgical treatments.
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